Skip to content

European Union Regulation

In the European Union, “CE marked” is not the same regulatory statement as “FDA approved.” CE marking follows conformity assessment under the applicable device framework; exact intended use and company roles still come from the current certificate, declaration of conformity, IFU, labeling, and EUDAMED or competent-authority records.

Review date: July 31, 2026.

The European Commission describes notified bodies as organizations designated by Member States to perform required conformity-assessment tasks before qualifying products are placed on the market (European Commission 🔗).

On May 28, 2026, EUDAMED’s actor, UDI/device, notified-body and certificate, and market-surveillance modules became mandatory. The remaining vigilance and clinical-investigation modules are still under development (EUDAMED overview 🔗).

ProductEvidence reviewedWhat it supportsLimitation
SculptraGalderma December 5, 2025 EU MDR announcementMDR certification and expansion to four named body areasUse current certificate and IFU for exact scope
LanlumaCurrent Sinclair regional professional pageCE 1023, GANA R&D manufacturer, and intended-use wordingA commercial page does not replace certificate and IFU review
AestheFillREGEN April 2021 company noticeCompany-reported CE certificate milestoneCurrent MDR/MDD status, certificate number, and scope not established here
JuvelookItalian Ministry of Health safety-notice recordDevice identity and VAIM manufacturer role in an EU safety recordDoes not by itself establish current CE certificate or intended use
RadiesseMerz official historical CE announcementsCE milestone in 2004 and Radiesse Lidocaine CE mark in 2016Current exact certificate, variant, and IFU remain necessary
EllanséCurrent Sinclair professional pageEU intended use, CE 0344, and AQTIS Medical B.V. manufacturerVerify exact current variant and governing IFU

Galderma announced EU MDR certification on December 5, 2025 and stated that the certified scope expanded from the face to the gluteal area, posterior thighs, décolletage, and upper arms (Galderma announcement 🔗).

This EU development does not establish FDA or Korean approval for the same body areas.

Sinclair’s current regional Lanluma page displays CE 1023 and describes Lanluma as a PLLA implant for increasing volume in depressed areas, particularly skin depressions (Sinclair Lanluma 🔗).

Sinclair’s current Ellansé page states an EU intended use for subdermal facial implantation to correct wrinkles and facial aging signs or conditions, and identifies CE 0344 and AQTIS Medical B.V. as manufacturer (Sinclair Ellansé 🔗).

Regional commercial copy may contain broader treatment discussion. Preserve the narrower intended-use statement and current IFU.

REGEN reported that AestheFill and PowerFill obtained a CE certificate in April 2021 (REGEN notice 🔗). Because the notice does not supply the complete current certificate scope, use it as a company-reported milestone rather than a full 2026 regulatory record.

The Italian Ministry of Health hosts a Juvelook field-safety record received September 3, 2024 and updated December 2, 2025, identifying VAIM Co., Ltd. as manufacturer (Italian Ministry of Health 🔗). A safety notice establishes a regulatory relationship to the device; it does not by itself prove the current certificate scope.

Merz states that Radiesse received a European aesthetic CE mark in 2004 and Radiesse Lidocaine received CE marking in 2016 (Merz announcement 🔗). These dated milestones should not replace the current variant’s certificate and IFU.

For a defensible current record, collect:

  1. Basic UDI-DI or exact device identifier
  2. manufacturer and EU authorized representative
  3. applicable MDR or legacy MDD status
  4. certificate number, notified body, scope, issue, and expiry dates
  5. declaration of conformity
  6. current language-specific IFU and intended use
  7. relevant EUDAMED and national competent-authority records

Return to the regional overview before translating an EU conformity statement into another jurisdiction.